Time to capitalise on Hikma’s ongoing (share price) momentum
17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."
Pages
54
Language
English
Published on
17/05/24
You may also be interested by these reports :
20/07/26
Bachem (ADD; Switzerland) is a peptide and oligonucleotide manufacturer, regarded as the most reliable partner in western economies as one of the few ...
20/07/26
Samsung Biologics announced a tender offer to acquire PolyPeptide Group for CHF 44.31/share, or CHF 1.46bn in market capitalisation, a premium of 6% ...
14/07/26
Pharmas’ AI investments pour broadly into two areas: Compute infrastructure, and AI models and platforms. Neither provides a long-term competitive ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...